Skip to main content
. 2016 Oct 7;95(40):e5085. doi: 10.1097/MD.0000000000005085

Figure 5.

Figure 5

Proliferation of human prostate cancer cells is reduced when ADAM28 is pharmacologically inhibited by KB-R7785 or silenced by siRNA transfection. (A) Proliferation (cells/mL) of DU145 cells treated with KB-R7785 (5 μM) or DMSO (vehicle control) over a time course of 7 days, and (B) proliferation (optical density at 490 nm) of LNCaP cells treated with KB-R7785 (1 μM) or DMSO (vehicle control) over 7 days. ∗P < 0.006, ∗∗P < 0.007, (∗∗∗P < 0.002; DMSO vs KB-R7785 for day 3 and 5); Mann–Whitney. Data are presented as a box and whisker plot (A and B), n = 3–8. (C) Graph depicts proliferation (optical density) of LNCaP cells when transiently transfected with ADAM28 siRNA or Cy3 scrambled control over 7 days. The proliferation of ADAM28ii siRNA transfected LNCaP prostate cancer cells (dark gray) is significantly reduced when compared to the Cy3 scrambled control (light gray) for all time-points. All P values < 0.000004; n = 7–8. Data are presented as a box and whisker plot. ADAM = a disintegrin and metalloproteinase, DMSO = dimethyl sulfoxide, siRNA = short-interfering RNA, SEM = standard error of mean.